Primary Hypercholesterolaemia/Homozygous Familial Hypercholesterolaemia (HoFH):
ROSETEMIB S.K is indicated for substitution therapy in adult patients who are adequately controlled with rosuvastatin and ezetimibe given concurrently at the same dose level as in the fixed combination, but as separate products, as adjunct to diet for treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) or homozygous familial hypercholesterolaemia.
